Feifei Luo
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 5%
- Immune cells in cancer
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Response and Inflammation
Papers in
- Oncology 21
- CAR-T cell therapy research 8
- Cancer Immunotherapy and Biomarkers 7
- Immunology 17
- Immunotherapy and Immune Responses 9
- Immune cells in cancer 4
- T-cell and B-cell Immunology 3
- Co-authors
- Yiwei Chu (24 shared papers)Jiao Yang (10 shared papers)Yuedi Wang (9 shared papers)Jiawen Qian (10 shared papers)Ronghua Liu (4 shared papers)Yuting Deng (7 shared papers)Chujun Julia Zhao (2 shared papers)Luman Wang (5 shared papers)
In The Last Decade
Feifei Luo
50 papers receiving 2k citations
Feifei Luo's Hit Papers
Peers
Comparison fields: 5 of 85
- Oncology 679
- Immunology 566
- Genetics 235
- Cancer Research 145
- Drug Discovery 3
Countries citing papers authored by Feifei Luo
This map shows the geographic impact of Feifei Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Luo more than expected).
Fields of papers citing papers by Feifei Luo
This network shows the impact of papers produced by Feifei Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Luo. The network helps show where Feifei Luo may publish in the future.
Co-authors
The 25 scholars most cited alongside Feifei Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 221 | |
| 2 | 2020 | 148 | |
| 3 | 2011 | 107 | |
| 4 | 2017 | 94 | |
| 5 | 2018 | 92 | |
| 6 | 2018 | 91 | |
| 7 | 2022 | 89 | |
| 8 | 2018 | 84 | |
| 9 | 2021 | 76 | |
| 10 | 2017 | 73 | |
| 11 | 2019 | 70 | |
| 12 | 2011 | 60 | |
| 13 | 2018 | 55 | |
| 14 | 2015 | 52 | |
| 15 | Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy Hit paper breakdown → | 2025 | 52 |
| 16 | 2019 | 46 | |
| 17 | 2024 | 45 | |
| 18 | 2011 | 39 | |
| 19 | 2017 | 39 | |
| 20 | 2023 | 33 |
About Feifei Luo
Feifei Luo is a scholar working on Oncology, Immunology, Genetics, Biomaterials and Neurology, having authored 50 papers that have together received 2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (9 papers), CAR-T cell therapy research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Immune cells in cancer (4 papers), Glioma Diagnosis and Treatment (4 papers), T-cell and B-cell Immunology (3 papers), Nanoparticle-Based Drug Delivery (3 papers) and Inflammatory Bowel Disease (3 papers). The work is most often cited by research in Oncology (679 citations), Immunology (566 citations), Genetics (235 citations), Cancer Research (145 citations) and Drug Discovery (3 citations). Feifei Luo has collaborated with scholars based in China, Belgium and Macao. Frequent co-authors include Yiwei Chu, Jiao Yang, Yuedi Wang, Jiawen Qian, Ronghua Liu, Yuting Deng, Chujun Julia Zhao, Luman Wang, Yufei Zhang and Jie Liu. Their work appears in journals such as Frontiers in Immunology, Cancer Immunology Immunotherapy, International Immunopharmacology, Cellular and Molecular Immunology and Signal Transduction and Targeted Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.